A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels
Authors
Keywords
-
Journal
Internal Medicine
Volume 62, Issue 20, Pages 3057-3062
Publisher
Japanese Society of Internal Medicine
Online
2023-10-15
DOI
10.2169/internalmedicine.0569-22
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical significance of serum levels of anti‐transcriptional intermediary factor 1‐γ antibody in patients with dermatomyositis
- (2020) Nobuaki Ikeda et al. JOURNAL OF DERMATOLOGY
- Anti-transcription intermediary factor 1γ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer
- (2018) Mika Teraishi et al. International Journal of Rheumatic Diseases
- Evidence supports blind screening for internal malignancy in dermatomyositis
- (2018) Hayley Leatham et al. MEDICINE
- Recent advances in dermatomyositis-specific autoantibodies
- (2016) Manabu Fujimoto et al. CURRENT OPINION IN RHEUMATOLOGY
- Anti-TIF1-γ antibody and cancer-associated myositis
- (2016) Ayumi Hida et al. NEUROLOGY
- Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies
- (2016) Naoki Mugii et al. PLoS One
- Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features—a Comprehensive Review
- (2015) Yoshinao Muro et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Myositis-specific autoantibodies: an important tool to support diagnosis of myositis
- (2015) Z. Betteridge et al. JOURNAL OF INTERNAL MEDICINE
- Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis
- (2015) David F. Fiorentino et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis
- (2014) Kohei Azuma et al. Modern Rheumatology
- Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1γ in Regenerating Muscle
- (2014) Payam Mohassel et al. Arthritis & Rheumatology
- Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis
- (2011) Yasuhito Hamaguchi et al. ARCHIVES OF DERMATOLOGY
- Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection
- (2011) David Fiorentino et al. ARTHRITIS AND RHEUMATISM
- Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins
- (2011) Manabu Fujimoto et al. ARTHRITIS AND RHEUMATISM
- Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis
- (2011) Ernesto Trallero-Araguás et al. ARTHRITIS AND RHEUMATISM
- Idiopathic Inflammatory Myopathy Associated with Malignancy: A Retrospective Cohort of 151 Korean Patients with Dermatomyositis and Polymyositis
- (2011) M. W. SO et al. JOURNAL OF RHEUMATOLOGY
- Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan
- (2010) Yi-Ju Chen et al. ARTHRITIS RESEARCH & THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started